Luye Pharma´s Global Strategy For CNS-Focused Products Gathers Pace: Rotigotine Extended Release Microspheres Submitted to Japan´s PMDA for Clinical Trials Approval
(WorldNews China)

Luye Pharma announced that its new investigational drug, Rotigotine Extended Release Microspheres for Injection (LY03003) for the treatment of Parkinson`s disease has been submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for clinical trials approval. Meanwhile Phase III clinical trials for LY03003 in the U.S. and China are progressing smoothly. LY03003 is one of Luye Pharma`s key products in the central nervous system (CNS) therapeutic area and can produce Continuous Dopamine Stimulation (CDS) on a long-term basis. Luye Pharma has been developing the drug simultaneously in key strategic markets, such as the U.S., China, Europe and Japan, preparing to launch first...